# Study of Cavosonstat (N91115) in CF Patients Who Are Heterozygous for F508del-CFTR and a Gating Mutation and Being Treated With Ivacaftor

> **NCT02724527** · PHASE2 · UNKNOWN · sponsor: **Nivalis Therapeutics, Inc.** · enrollment: 19 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** Cavosonstat
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02724527
- **Lead sponsor:** Nivalis Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-04
- **Primary completion:** 2017-04
- **Final completion:** 2017-04
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2016-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02724527

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02724527, "Study of Cavosonstat (N91115) in CF Patients Who Are Heterozygous for F508del-CFTR and a Gating Mutation and Being Treated With Ivacaftor". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02724527. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*